Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2001 Sep;56(Suppl 2):ii38–ii44.

18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer

G Laking, P Price
PMCID: PMC1765989  PMID: 11514705

Full Text

The Full Text of this article is available as a PDF (145.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed N., Berridge M. V. Regulation of glucose transport by interleukin-3 in growth factor-dependent and oncogene-transformed bone marrow-derived cell lines. Leuk Res. 1997 Jul;21(7):609–618. doi: 10.1016/s0145-2126(97)00016-7. [DOI] [PubMed] [Google Scholar]
  2. Albanell J., Lonardo F., Rusch V., Engelhardt M., Langenfeld J., Han W., Klimstra D., Venkatraman E., Moore M. A., Dmitrovsky E. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst. 1997 Nov 5;89(21):1609–1615. doi: 10.1093/jnci/89.21.1609. [DOI] [PubMed] [Google Scholar]
  3. Bar-Shalom R., Valdivia A. Y., Blaufox M. D. PET imaging in oncology. Semin Nucl Med. 2000 Jul;30(3):150–185. doi: 10.1053/snuc.2000.7439. [DOI] [PubMed] [Google Scholar]
  4. Berlangieri S. U., Scott A. M., Knight S. R., Fitt G. J., Hennessy O. F., Tochon-Danguy H. J., Clarke C. P., McKay W. J. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur J Cardiothorac Surg. 1999 Sep;16 (Suppl 1):S25–S30. doi: 10.1016/s1010-7940(99)00179-7. [DOI] [PubMed] [Google Scholar]
  5. Beyer T., Townsend D. W., Brun T., Kinahan P. E., Charron M., Roddy R., Jerin J., Young J., Byars L., Nutt R. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000 Aug;41(8):1369–1379. [PubMed] [Google Scholar]
  6. Blettner M., Grosche B., Zeeb H. Occupational cancer risk in pilots and flight attendants: current epidemiological knowledge. Radiat Environ Biophys. 1998 Jul;37(2):75–80. doi: 10.1007/s004110050097. [DOI] [PubMed] [Google Scholar]
  7. Bury T., Dowlati A., Paulus P., Corhay J. L., Hustinx R., Ghaye B., Radermecker M., Rigo P. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J. 1997 Nov;10(11):2529–2534. doi: 10.1183/09031936.97.10112529. [DOI] [PubMed] [Google Scholar]
  8. Chen Y. H., Gao W., Zhou T., Zhao W., Zhao H., Liu D., Felber E. Detection of bone marrow micrometastasis. Hybridoma. 1999 Oct;18(5):465–466. doi: 10.1089/hyb.1999.18.465. [DOI] [PubMed] [Google Scholar]
  9. Chin R., Jr, Ward R., Keyes J. W., Choplin R. H., Reed J. C., Wallenhaupt S., Hudspeth A. S., Haponik E. F. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2090–2096. doi: 10.1164/ajrccm.152.6.8520780. [DOI] [PubMed] [Google Scholar]
  10. Dewan N. A., Shehan C. J., Reeb S. D., Gobar L. S., Scott W. J., Ryschon K. Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. Chest. 1997 Aug;112(2):416–422. doi: 10.1378/chest.112.2.416. [DOI] [PubMed] [Google Scholar]
  11. Di Chiro G., DeLaPaz R. L., Brooks R. A., Sokoloff L., Kornblith P. L., Smith B. H., Patronas N. J., Kufta C. V., Kessler R. M., Johnston G. S. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology. 1982 Dec;32(12):1323–1329. doi: 10.1212/wnl.32.12.1323. [DOI] [PubMed] [Google Scholar]
  12. Dietlein M., Weber K., Gandjour A., Moka D., Theissen P., Lauterbach K. W., Schicha H. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med. 2000 Nov;27(11):1598–1609. doi: 10.1007/s002590000376. [DOI] [PubMed] [Google Scholar]
  13. Dwamena B. A., Sonnad S. S., Angobaldo J. O., Wahl R. L. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. Radiology. 1999 Nov;213(2):530–536. doi: 10.1148/radiology.213.2.r99nv46530. [DOI] [PubMed] [Google Scholar]
  14. Farrell M. A., McAdams H. P., Herndon J. E., Patz E. F., Jr Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Radiology. 2000 Jun;215(3):886–890. doi: 10.1148/radiology.215.3.r00jn29886. [DOI] [PubMed] [Google Scholar]
  15. Forozan F., Karhu R., Kononen J., Kallioniemi A., Kallioniemi O. P. Genome screening by comparative genomic hybridization. Trends Genet. 1997 Oct;13(10):405–409. doi: 10.1016/s0168-9525(97)01244-4. [DOI] [PubMed] [Google Scholar]
  16. Fukuse T., Hirata T., Naiki H., Hitomi S., Wada H. Prognostic significance of proliferative activity in pN2 non-small-cell lung carcinomas and their mediastinal lymph node metastases. Ann Surg. 2000 Jul;232(1):112–118. doi: 10.1097/00000658-200007000-00016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gambhir S. S., Hoh C. K., Phelps M. E., Madar I., Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med. 1996 Sep;37(9):1428–1436. [PubMed] [Google Scholar]
  18. Ginsberg R. J., Hill L. D., Eagan R. T., Thomas P., Mountain C. F., Deslauriers J., Fry W. A., Butz R. O., Goldberg M., Waters P. F. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg. 1983 Nov;86(5):654–658. [PubMed] [Google Scholar]
  19. Guhlmann A., Storck M., Kotzerke J., Moog F., Sunder-Plassmann L., Reske S. N. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET). Thorax. 1997 May;52(5):438–441. doi: 10.1136/thx.52.5.438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gupta N. C., Graeber G. M., Rogers J. S., 2nd, Bishop H. A. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann Surg. 1999 Feb;229(2):286–291. doi: 10.1097/00000658-199902000-00018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hagberg R. C., Segall G. M., Stark P., Burdon T. A., Pompili M. F. Characterization of pulmonary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose positron emission tomography. Eur J Cardiothorac Surg. 1997 Jul;12(1):92–97. doi: 10.1016/s1010-7940(97)00159-0. [DOI] [PubMed] [Google Scholar]
  22. Higashi K., Nishikawa T., Seki H., Oguchi M., Nambu Y., Ueda Y., Yuasa K., Tonami H., Okimura T., Yamamoto I. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer. J Nucl Med. 1998 Jan;39(1):9–15. [PubMed] [Google Scholar]
  23. Hoffman P. C., Mauer A. M., Vokes E. E. Lung cancer. Lancet. 2000 Feb 5;355(9202):479–485. doi: 10.1016/S0140-6736(00)82038-3. [DOI] [PubMed] [Google Scholar]
  24. Kalff V., Hicks R. J., MacManus M. P., Binns D. S., McKenzie A. F., Ware R. E., Hogg A., Ball D. L. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol. 2001 Jan 1;19(1):111–118. doi: 10.1200/JCO.2001.19.1.111. [DOI] [PubMed] [Google Scholar]
  25. Kernstine K. H., Stanford W., Mullan B. F., Rossi N. P., Thompson B. H., Bushnell D. L., McLaughlin K. A., Kern J. A. PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. Ann Thorac Surg. 1999 Sep;68(3):1022–1028. doi: 10.1016/s0003-4975(99)00788-2. [DOI] [PubMed] [Google Scholar]
  26. Kutlu C. A., Pastorino U., Maisey M., Goldstraw P. Selective use of PET scan in the preoperative staging of NSCLC. Lung Cancer. 1998 Sep;21(3):177–184. doi: 10.1016/s0169-5002(98)00026-9. [DOI] [PubMed] [Google Scholar]
  27. Laroche C., Wells F., Coulden R., Stewart S., Goddard M., Lowry E., Price A., Gilligan D. Improving surgical resection rate in lung cancer. Thorax. 1998 Jun;53(6):445–449. doi: 10.1136/thx.53.6.445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Lonneux M., Delval D., Bausart R., Moens R., Willockx R., Van Mael P., Declerck P., Jamar F., Zreik H., Pauwels S. Can dual-headed 18F-FDG SPET imaging reliably supersede PET in clinical oncology? A comparative study in lung and gastrointestinal tract cancer. Nucl Med Commun. 1998 Nov;19(11):1047–1054. doi: 10.1097/00006231-199811000-00004. [DOI] [PubMed] [Google Scholar]
  29. Marom E. M., McAdams H. P., Erasmus J. J., Goodman P. C., Culhane D. K., Coleman R. E., Herndon J. E., Patz E. F., Jr Staging non-small cell lung cancer with whole-body PET. Radiology. 1999 Sep;212(3):803–809. doi: 10.1148/radiology.212.3.r99se21803. [DOI] [PubMed] [Google Scholar]
  30. Mathupala S. P., Rempel A., Pedersen P. L. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr. 1997 Aug;29(4):339–343. doi: 10.1023/a:1022494613613. [DOI] [PubMed] [Google Scholar]
  31. Parkin D. M., Pisani P., Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1. doi: 10.3322/canjclin.49.1.33. [DOI] [PubMed] [Google Scholar]
  32. Parkin D. M., Sankaranarayanan R. Overview on small cell lung cancer in the world: industrialized countries, Third World, eastern Europe. Anticancer Res. 1994 Jan-Feb;14(1B):277–282. [PubMed] [Google Scholar]
  33. Patz E. F., Jr, Lowe V. J., Goodman P. C., Herndon J. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest. 1995 Dec;108(6):1617–1621. doi: 10.1378/chest.108.6.1617. [DOI] [PubMed] [Google Scholar]
  34. Pieterman R. M., van Putten J. W., Meuzelaar J. J., Mooyaart E. L., Vaalburg W., Koëter G. H., Fidler V., Pruim J., Groen H. J. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000 Jul 27;343(4):254–261. doi: 10.1056/NEJM200007273430404. [DOI] [PubMed] [Google Scholar]
  35. Rosell R. Staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000 Nov 23;343(21):1572–1573. [PubMed] [Google Scholar]
  36. Salerno C. T., Frizelle S., Niehans G. A., Ho S. B., Jakkula M., Kratzke R. A., Maddaus M. A. Detection of occult micrometastases in non-small cell lung carcinoma by reverse transcriptase-polymerase chain reaction. Chest. 1998 Jun;113(6):1526–1532. doi: 10.1378/chest.113.6.1526. [DOI] [PubMed] [Google Scholar]
  37. Sasaki M., Ichiya Y., Kuwabara Y., Akashi Y., Yoshida T., Fukumura T., Murayama S., Ishida T., Sugio K., Masuda K. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med. 1996 Jul;23(7):741–747. doi: 10.1007/BF00843701. [DOI] [PubMed] [Google Scholar]
  38. Saunders C. A., Dussek J. E., O'Doherty M. J., Maisey M. N. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg. 1999 Mar;67(3):790–797. doi: 10.1016/s0003-4975(98)01257-0. [DOI] [PubMed] [Google Scholar]
  39. Sazon D. A., Santiago S. M., Soo Hoo G. W., Khonsary A., Brown C., Mandelkern M., Blahd W., Williams A. J. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med. 1996 Jan;153(1):417–421. doi: 10.1164/ajrccm.153.1.8542152. [DOI] [PubMed] [Google Scholar]
  40. Scott W. J., Gobar L. S., Terry J. D., Dewan N. A., Sunderland J. J. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg. 1996 Mar;111(3):642–648. doi: 10.1016/s0022-5223(96)70317-3. [DOI] [PubMed] [Google Scholar]
  41. Smith T. A. Facilitative glucose transporter expression in human cancer tissue. Br J Biomed Sci. 1999;56(4):285–292. [PubMed] [Google Scholar]
  42. Sokoloff L., Reivich M., Kennedy C., Des Rosiers M. H., Patlak C. S., Pettigrew K. D., Sakurada O., Shinohara M. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977 May;28(5):897–916. doi: 10.1111/j.1471-4159.1977.tb10649.x. [DOI] [PubMed] [Google Scholar]
  43. Som P., Atkins H. L., Bandoypadhyay D., Fowler J. S., MacGregor R. R., Matsui K., Oster Z. H., Sacker D. F., Shiue C. Y., Turner H. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med. 1980 Jul;21(7):670–675. [PubMed] [Google Scholar]
  44. Steinert H. C., Hauser M., Allemann F., Engel H., Berthold T., von Schulthess G. K., Weder W. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology. 1997 Feb;202(2):441–446. doi: 10.1148/radiology.202.2.9015071. [DOI] [PubMed] [Google Scholar]
  45. Stokkel M. P., Bakker P. F., Heine R., Schlösser N. J., Lammers J. W., Van Rijk P. P. Staging of lymph nodes with FDG dual-headed PET in patients with non-small-cell lung cancer. Nucl Med Commun. 1999 Nov;20(11):1001–1007. doi: 10.1097/00006231-199911000-00004. [DOI] [PubMed] [Google Scholar]
  46. Tatsumi M., Yutani K., Watanabe Y., Miyoshi S., Tomiyama N., Johkoh T., Kusuoka H., Nakamura H., Nishimura T. Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET. J Nucl Med. 1999 Apr;40(4):566–573. [PubMed] [Google Scholar]
  47. Valk P. E., Pounds T. R., Hopkins D. M., Haseman M. K., Hofer G. A., Greiss H. B., Myers R. W., Lutrin C. L. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg. 1995 Dec;60(6):1573–1582. doi: 10.1016/0003-4975(95)00752-0. [DOI] [PubMed] [Google Scholar]
  48. Valk P. E. Randomized controlled trials are not appropriate for imaging technology evaluation. J Nucl Med. 2000 Jul;41(7):1125–1126. [PubMed] [Google Scholar]
  49. Vansteenkiste J. F., Stroobants S. G., De Leyn P. R., Dupont P. J., Bogaert J., Maes A., Deneffe G. J., Nackaerts K. L., Verschakelen J. A., Lerut T. E. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 1998 Jun;16(6):2142–2149. doi: 10.1200/JCO.1998.16.6.2142. [DOI] [PubMed] [Google Scholar]
  50. Wahl R. L., Quint L. E., Greenough R. L., Meyer C. R., White R. I., Orringer M. B. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology. 1994 May;191(2):371–377. doi: 10.1148/radiology.191.2.8153308. [DOI] [PubMed] [Google Scholar]
  51. Watanabe Y., Shimizu J., Tsubota M., Iwa T. Mediastinal spread of metastatic lymph nodes in bronchogenic carcinoma. Mediastinal nodal metastases in lung cancer. Chest. 1990 May;97(5):1059–1065. doi: 10.1378/chest.97.5.1059. [DOI] [PubMed] [Google Scholar]
  52. Weder W., Schmid R. A., Bruchhaus H., Hillinger S., von Schulthess G. K., Steinert H. C. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg. 1998 Sep;66(3):886–893. doi: 10.1016/s0003-4975(98)00675-4. [DOI] [PubMed] [Google Scholar]
  53. Weng E., Tran L., Rege S., Safa A., Sadeghi A., Juillard G., Mark R., Santiago S., Brown C., Mandelkern M. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer. Am J Clin Oncol. 2000 Feb;23(1):47–52. doi: 10.1097/00000421-200002000-00014. [DOI] [PubMed] [Google Scholar]
  54. Younes R. N., Gross J. L., Deheinzelin D. Follow-up in lung cancer: how often and for what purpose? Chest. 1999 Jun;115(6):1494–1499. doi: 10.1378/chest.115.6.1494. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES